LY75抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P10804(LY75 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

**Background of LY75 Antibody**

LY75. also known as DEC-205 or CD205. is a type I transmembrane C-type lectin receptor belonging to the macrophage mannose receptor family. It is predominantly expressed on antigen-presenting cells (APCs), such as dendritic cells (DCs) and macrophages, where it plays a critical role in antigen capture, processing, and presentation via MHC class I/II molecules. Structurally, LY75 contains multiple ligand-binding domains, including a cysteine-rich region and fibronectin type II repeats, enabling it to bind glycosylated antigens and immune complexes.

LY75 antibodies are tools designed to target this receptor for research or therapeutic purposes. In research, anti-LY75 antibodies help study DC biology, antigen uptake mechanisms, and immune tolerance. Therapeutically, LY75 has been explored as a delivery target for vaccine adjuvants or immunotherapies. By conjugating antigens or drugs to LY75-specific antibodies, researchers aim to enhance APC-specific targeting, thereby improving antigen presentation and T-cell activation.

Preclinical studies highlight its potential in cancer immunotherapy, where LY75-targeted approaches have shown improved antitumor immune responses. However, its role in immune regulation remains complex, as LY75 may also mediate immunosuppressive signals in certain contexts. Overall, LY75 antibodies represent a versatile tool for modulating immune responses, with ongoing research focused on optimizing their specificity and efficacy in disease models.